Table 1. Demographics and treatment characteristics for patients with nasopharyngeal carcinoma.
| Characteristics | ALL | Leukocyte (×109/L) | Neutrophil (×109/L) | ||||
|---|---|---|---|---|---|---|---|
| (N, %) | Leukocyte≤10 (N, %) | Leukocyte >10 (N, %) | p value | neutrophil≤8 (N, %) | neutrophil>8 (N, %) | p value | |
| Total | 5854 | 5346(91.3) | 508 (8.7) | 5451(93.1) | 403 (6.9) | ||
| Gender | <0.001 | 0.001 | |||||
| Male | 4371(74.7) | 3950(73.9) | 421(82.9) | 4041(74.1) | 330(81.9) | ||
| Female | 1483(25.3) | 1396(26.1) | 87 (17.1) | 1410(25.9) | 73 (18.1) | ||
| Age | 0.52 | 0.085 | |||||
| ≤45 | 2997(51.2) | 2723(51.1) | 267(52.6) | 2774(49.1) | 223(55.3) | ||
| >45 | 2857(48.8) | 2616(48.9) | 241(47.4) | 2677(50.9) | 180(44.7) | ||
| T-classification | <0.001 | <0.001 | |||||
| T1 | 937(16.0) | 884(16.5) | 53 (10.4) | 894(16.4) | 43 (10.7) | ||
| T2 | 1279(21.8) | 1179(22.1) | 100(19.7) | 1198(22.0) | 81 (20.1) | ||
| T3 | 2127(36.3) | 1939(36.3) | 188(37.0) | 1990(36.5) | 137(34.0) | ||
| T4 | 1511(25.8) | 1344(25.1) | 167(32.9) | 1369(25.1) | 142(35.2) | ||
| N-classification | 0.004 | 0.026 | |||||
| N0 | 1133(19.4) | 1062(19.9) | 71 (14.0) | 1071(19.6) | 62 (15.4) | ||
| N1 | 3314(56.6) | 3012(56.3) | 302(59.4) | 3082(56.5) | 232(57.6) | ||
| N2 | 1119(19.1) | 1016(19.0) | 103(20.3) | 1034(19.0) | 85 (21.1) | ||
| N3 | 288(4.9) | 256(4.8) | 32 (6.3) | 264(4.8) | 24 (6.0) | ||
| Clinical stage | <0.001 | <0.001 | |||||
| I | 285(4.9) | 272(5.1) | 13 (2.6) | 274(5.0) | 11 (2.7) | ||
| II | 1442(24.6) | 1342(25.1) | 100(19.7) | 1363(25.0) | 79 (19.6) | ||
| III | 2395(40.9) | 2190(41.0) | 205 (40.4) | 2241(41.1) | 154(38.2) | ||
| IV | 1732(29.6) | 1542(28.8) | 190(37.4) | 1573(28.9) | 159(39.5) | ||
| Pathologic types | 0.803 | 0.128 | |||||
| I | 115(2.0) | 107(2.0) | 8 (1.6) | 111(2.0) | 4 (1.0) | ||
| II | 321(5.5) | 293(5.5) | 28 (5.5) | 304(5.6) | 17 (4.2) | ||
| III | 5418(92.6) | 4946(92.5) | 472(92.9) | 5036(92.4) | 382(94.8) | ||
| Radiotherapy | 0.746 | 0.847 | |||||
| CRT | 4013(68.6) | 3668(68.6) | 345(67.9) | 3735(68.5) | 278(69.0) | ||
| IMRT | 1841(31.4) | 1678(31.4) | 163(32.1) | 1716(31.0) | 125(31.0) | ||
| Chemotherapy | <0.001 | 0.001 | |||||
| No | 1084(18.5) | 1025(19.2) | 59 (11.6) | 1035(19.0) | 49 (12.2) | ||
| IC | 1282(21.9) | 1158(21.7) | 124(24.4) | 1190(21.8) | 92 (22.8) | ||
| CC | 1761(30.1) | 1617(30.2) | 144(28.3) | 1646(30.2) | 115(28.5) | ||
| IC+CC | 1472(25.1) | 1313(24.6) | 159(31.3) | 1350(24.8) | 122(30.3) | ||
| CC+AC | 255(4.4) | 233(4.4) | 22 (4.3) | 230(4.2) | 25 (6.2) | ||
CRT: conventional radiotherapy; IMRT: intensity modulated radiation therapy; IC: induced chemotherapy; CC: concurrent chemotherapy; AC: adjuvant chemotherapy